Why the study?
Does torasemide provide anti-aldosteronic and antifibrotic benefits compared to other diuretics in patients with chronic heart failure?
Does torasemide provide anti-aldosteronic and antifibrotic benefits compared to other diuretics in patients with chronic heart failure?
Torasemide may offer unique antifibrotic and anti-aldosteronic benefits in chronic heart failure compared to other loop diuretics like furosemide.
Answers are grounded in this paper and cite their sources.
Torasemide may reduce myocardial fibrosis in HF; hypothesis-generating and requires randomized confirmation before practice change.
The article discusses the torasemide pharmacokinetic characteristics which are favourably different from furosemide characteristics. We paid attention to the fact that torasemide had anti-aldosteronic and antifibrotic effects; all these characteristics were alien to other diuretics nature. The results of clinical studies showed torasemide ability to prevent the development and reverse myocardial fibrosis. Taking into account modern representations concerning the pathogenesis of chronic heart failure, in particular the role of diastolic dysfunction in developing haemodynamic compromise, we substantiated torasemide application as a part of complex pharmacotherapy of chronic heart failure in patients with elevated left ventricular filling pressure before the appearance of clinical manifestations of stagnation.
No takes yet. Share an insight, caveat, or question.
Н. Б. Перепеч (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: